The British pharmaceutical company and Alphabet's Verily Life Sciences, which was formally Google's life sciences division until last year, will together invest £540m over seven years in a new company, Galvani Bioelectronics.The firm will research and develop bioelectronic medicines for commercial use.Bioelectronics is a relatively new field and uses...